[ A21-164] Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 07.07.2022
Commission awarded on 14.12.2021 by the Federal Joint Committee (G-BA).
Adult patients with advanced or recurrent endometrial cancer whose disease has progressed during or after prior platinum-based therapy at any stage of the disease when surgery or radiation to cure the cancer is not an option for them
- Patients for whom doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: indication of a considerable added benefit
- Patients for whom a therapy option other than doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-04-19.